Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Background: CCTG PA.7 (NCT02879318) was a randomized phase II trial comparing gemcitabine (G) and nab-paclitaxel (N) with and without dual immune checkpoint inhibition with durvalumab (D) and ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating ...

Background: The standard STUPP regimen (radiotherapy with temozolomide [TMZ] followed by adjuvant TMZ) remains limited in efficacy for newly diagnosed glioblastoma (GBM). Anlotinib, a multi-kinase ...

Background: T-DXd is an antibody-drug conjugate approved for advanced HER2+/low/ultra-low breast cancer and multiple other solid tumors. T-DXd carries a rare but serious risk of ILD (incidence 12-15%) ...

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

Background: Trophoblast cell surface antigen 2 (Trop-2), encoded by the transmembrane calcium signal transducer gene, TACSTD2, is highly expressed in many cancers, including endometrial cancer ...

Background: ASC, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket, recently received FDA Accelerated Approval for newly diagnosed CML-CP based on major molecular response ...

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. Pooled ...

Background: Effective therapy following frontline immune checkpoint inhibitor (ICI)-based treatment for advanced non-small cell lung cancer (NSCLC) is needed as limited options are available. Lung-MAP ...

Antitumor effect of PRaG therapy in a triple-negative breast cancer model. Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced ...